Clinical trialsCompany release
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
🇺🇸 Inhibrx Biosciences, Inc. (INBX) · Tue 17 Nov 2026
Updated Phase 1/2 expansion data show a 62.7% ORR and 6.0-month median PFS in 51 evaluable patients, with FDA discussions planned.
Inhibrx Biosciences released updated Phase 1/2 expansion data on 17 November 2026 for ozekibart (INBRX-109), a tetravalent DR5 agonist, combined with irinotecan and temozolomide in relapsed or refractory Ewing sarcoma.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Inhibrx Biosciences, Inc. ↗
Article written by VigiEye from the official source (Inhibrx Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026